T-Cell Therapy and CAR-T Overview

CAR-T cells are the most clinically and commercially advanced of the anti-cancer cell therapies. While incredibly effective, they have faced multiple challenges.

At Nanotein work to address these challenges with our innovative reagents for CAR-T cell therapies help customers to avoid treatment manufacturing failures and the production of therapeutic doses that only deliver short lived and/or poor treatment outcomes.

6
5
4
3
2
1 1

HIGHLY EFFICIENT

Our technology is able to produce larger quantities of CAR-T cells in less time than competitor reagents.

lower risk (Soluble + Protein based)

We use protein-based components in our manufacturing, eliminating the risk of synthetic contaminants.

Improved Clinical Outcomes

Clinical research showed high rates of tumor destruction and remission in patients by the types of T cell profile Nanotein’s product expands.

HIGHLY EFFICIENT

Our technology is able to produce larger quantities of CAR-T cells in less time than competitor reagents.

lower risk (Soluble + Protein based)

We use protein-based components in our manufacturing, eliminating the risk of synthetic contaminants.

Improved Clinical Outcomes

Clinical research showed high rates of tumor destruction and remission in patients by the types of T cell profile Nanotein’s product expands.

mAb12 only
mAb11 only
mAb10 only
mAb9 only
mAb8 only
mAb7 only
mAb6 only
mAb5 only
mAb4 only
mAb3 only
mAb2 only
mAb1 only
nano only